60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
60 Degrees Pharmaceuticals, Inc. Common Stock stock (SXTP) is currently trading at $1.42. 60 Degrees Pharmaceuticals, Inc. Common Stock PS ratio (Price-to-Sales) is 2.57. Analyst consensus price target for SXTP is $17.60. WallStSmart rates SXTP as Sell.
- SXTP PE ratio analysis and historical PE chart
- SXTP PS ratio (Price-to-Sales) history and trend
- SXTP intrinsic value — DCF, Graham Number, EPV models
- SXTP stock price prediction 2025 2026 2027 2028 2029 2030
- SXTP fair value vs current price
- SXTP insider transactions and insider buying
- Is SXTP undervalued or overvalued?
- 60 Degrees Pharmaceuticals, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- SXTP Piotroski F-Score and Altman Z-Score
- SXTP analyst price target and Smart Rating
60 Degrees Pharmaceuticals, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) Key Strengths (1)
Revenue surging 256.90% year-over-year
Supporting Valuation Data
60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very low institutional interest at 5.59%
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 2.57x sales
Supporting Valuation Data
60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 256.90%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Institutional Own.. Some valuation metrics including Price/Sales (2.57) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -154.80%, Operating Margin at -440.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -154.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 256.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SXTP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SXTP's Price-to-Sales ratio of 2.57x sits near its historical average of 2.57x (43th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 27% below its historical high of 3.53x set in Mar 2026, and 33% above its historical low of 1.93x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~2.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
60 Degrees Pharmaceuticals, Inc. Common Stock is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 1M with 257% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 257% YoY, reaching 1M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 59% of revenue (809,777) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can 60 Degrees Pharmaceuticals, Inc. Common Stock maintain 257%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 3.03, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact 60 Degrees Pharmaceuticals, Inc. Common Stock.
Bottom Line
60 Degrees Pharmaceuticals, Inc. Common Stock is a high-conviction growth story with revenue accelerating at 257% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:24:03 AM
About 60 Degrees Pharmaceuticals, Inc. Common Stock(SXTP)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company is headquartered in Washington, District of Columbia.